Beyond output and employment: The impact of America’s biopharmaceutical industry
By Ryan Garofalo | February 11, 2021
Particularly in recent times, biopharmaceutical companies have become increasingly important to the American economy. But just how valuable are they? In the United States, these businesses support...
Read More
Preserving U.S. innovation worldwide is more important than ever
By Megan Van Etten | January 29, 2021
The COVID-19 pandemic has spurred unprecedented levels of innovation within the biopharmaceutical industry to combat this urgent global health crisis. PhRMA member companies are collaborating with...
Read More
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
By Nicole Longo | December 21, 2020
As the world has grappled with the current pandemic, there has been increased focus on biopharmaceutical manufacturing and its global supply chain. Many wondered whether the biopharmaceutical...
Read More
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
By Megan Van Etten | October 2, 2020
The first Friday of October marks Manufacturing Day, an annual recognition of the critical role manufacturing industries play in powering innovation and generating jobs and economic growth for...
Read More
America’s global leadership in biopharmaceutical manufacturing
By Nicole Longo | June 4, 2020
Unfortunately, there are a lot of assertions floating around that tell a misleading story about pharmaceutical manufacturing, diminishing America’s leadership and suggesting our reliance on other...
Read More
New report: Biopharmaceutical industry supports over 4 million jobs and $1.1 trillion in U.S. economic output
By Sarah Sutton | February 12, 2020
Across the country, the biopharmaceutical sector supports millions of jobs in its pursuit to discover ground-breaking treatments and cures for patients around the world.
Read More
What you need to know about H.R. 3
By Tom Wilbur | December 12, 2019
Speaker of the House Nancy Pelosi’s drug pricing proposal, H.R. 3, which is being voted on in the U.S. House of Representatives today, is unprecedented in size and scope. It dramatically expands...
Read More
New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines
By Nicole Longo | December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...
Read More
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
By Tom Wilbur | November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...
Read More
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
By Tom Wilbur | October 31, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be the wrong approach for patients, the U.S. health care system and the economy.
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
